Opinion|Videos|June 9, 2025
The ZIRCON Trial
Panelists discuss how the ZIRCON trial demonstrated high positive predictive value (> 90%) for identifying clear cell renal cell carcinoma using a new molecular imaging agent, though negative predictive value was lower at approximately 70%.
Advertisement
Episodes in this series
The ZIRCON Trial and Molecular Imaging
Main Discussion Topics:
- The ZIRCON trial evaluated a novel PET tracer (89Zr-TLX250) for characterizing small renal masses.
- The trial demonstrated high sensitivity and specificity for identifying clear cell renal cell carcinoma (ccRCC).
- Positive predictive value exceeded 90% for ccRCC.
- Negative predictive value was less impressive, with 30% still having ccRCC when test negative.
Key Points for Physicians:
- 89Zr-TLX250 PET showed greater than 85% accuracy for identifying ccRCC.
- Positive predictive value of greater than 90% indicates high reliability when positive.
- Negative predictive value was approximately 70%.
- Represents entry into the “molecular era” of kidney cancer imaging
Notable Insights:
The high positive predictive value makes this a potentially valuable test when positive, though negative tests require careful interpretation.
Clinical Significance:
This molecular imaging approach represents a significant advance in noninvasive characterization of renal masses and may reduce unnecessary interventions.
Advertisement
Related to this article
OpenFlo incorporates a design that modifies key mechanical features of conventional Foley catheters.
Study design discussions can help patients weigh personalized marketing claims, according to Jean Cunningham, PharmD, BCPS.
VIR-5500 is a PSMA-targeted PRO-XTEN dual-masked T-cell engager entering phase 3 development for prostate cancer.
Marie-Pier St-Laurent, MD, FRCSC, explains how NeoBLAST combines imaging, TURBT, and ctDNA to identify candidates for bladder-sparing surveillance.
Bladder symptoms during IVF often reflect hormonal and pelvic floor changes, not infection, according to Aleece Fosnight, MSPAS, PA-C.
A national survey found US hospitals expanded CAUTI prevention over 20 years, but use of key catheter-removal strategies remains variable.
Rezūm improved symptoms and quality of life at 1 year vs combination pharmacotherapy in sexually active men with BPO while preserving sexual function.
Sri Sivalingam, MD, discusses how suction-based technologies are improving stone clearance and raising expectations for ureteroscopic stone treatment.
Advertisement
Advertisement